Impact of radiocontaminants in commercially available iodine-123: dosimetric evaluation.
Impact of radiocontaminants in commercially available iodine-123: dosimetric evaluation.
复制标题
市售碘 123 中放射性污染物的影响：剂量测定评估。
DOI：
--
复制
发表时间：
1986
影响因子：
9.3
通讯作者：
J. M. Gochoco
中科院分区：
文献类型：
--
作者：
H. Ziessman;F. Fahey;J. M. Gochoco
碘-123(123I)因其理想的物理和生物学特性以及对甲状腺的低辐射吸收剂量而被一些人认为是甲状腺闪烁成像的首选放射性核素。然而，市售的123I(p，2n)和(p，5n)具有放射性污染物。MIRD公式被用来估计不同年龄组在交付时接受推荐给药活动的甲状腺吸收剂量，以及假设供应商指定的辐射污染水平的两个半衰期。计算表明，与123I(p，2n)扫描和摄取相比，在投放时用~(131)I-99m扫描摄取~(131)I对甲状腺的吸收剂量更少。在两个半衰期，吸收剂量是131I扫描剂量的三倍，并变得相当于131I扫描的剂量。两个半衰期的~(123)I(p，5n)扫描的吸收剂量高于~(123)I(p，2n)扫描的剂量。碘-123胶囊不应为了获得推荐的儿科给药活动而腐烂。对于成人或大多数儿童来说，商用的123I用于甲状腺闪烁成像似乎没有剂量学上的优势。
Iodine-123 (123I) is considered by some to be the radionuclide of choice for thyroid scintigraphy because of its ideal physical and biological characteristics and low radiation absorbed dose to the thyroid. However, commercially available 123I (p,2n) and (p,5n) have radiocontaminants. The MIRD formalism was used to estimate the absorbed dose to the thyroid for various age groups receiving recommended administered activities at the time of delivery and at two half-lives assuming radiocontamination levels specified by the suppliers. The calculations demonstrate that an 131I uptake with a technetium-99m scan at the time of delivery results in less absorbed dose to the thyroid than an 123I (p,2n) scan and uptake. At two half-lives the absorbed dose triples and becomes equivalent to the dose from an 131I scan. The absorbed dose from an 123I (p,5n) scan at two half-lives is higher than that of an 123I (p,2n) scan at the time of delivery. Iodine-123 capsules should not be decayed down in order to obtain a recommended pediatric administered activity. There appears to be no dosimetric advantage of commercially available 123I for thyroid scintigraphy for adults or most children.